Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver entities : Akero therapeutics, inc. save search
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
Published: 2023-11-10 (Crawled : 14:00) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: -1.26%
meeting liver therapeutics
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins
Published: 2023-10-10 (Crawled : 11:00) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: -59.06%
H: 0.0%
C: -8.66%
liver fibrosis therapeutics results insulin nash
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight
Published: 2023-07-12 (Crawled : 21:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 1.7%
H: 0.01%
C: -0.32%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.08%
H: 0.46%
C: -1.26%
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: 0.41%
H: 3.34%
C: 1.43%
LPCN | $5.33 -2.02% -2.06% 11K
|
Health Technology
|
| O: 0.11%
H: 2.15%
C: 1.02%
GALT | $3.37 -0.3% -0.3% 210K
|
Health Technology
|
| O: 0.64%
H: 7.01%
C: 5.1%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.69%
H: 1.02%
C: 0.29%
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.78%
H: 1.1%
C: -0.15%
cirrhosis liver growth market
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
Published: 2023-06-23 (Crawled : 11:00) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: -0.79%
H: 0.5%
C: -1.49%
liver international therapeutics study
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category
Published: 2022-11-07 (Crawled : 13:20) - biospace.com/
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 2.39%
H: 2.39%
C: -3.12%
meeting liver therapeutics presentation today study
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
Published: 2022-11-07 (Crawled : 13:00) - ir.akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 2.39%
H: 2.39%
C: -3.12%
meeting liver therapeutics today
Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology
Published: 2022-06-27 (Crawled : 12:00) - biospace.com/
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.0%
H: 0.87%
C: -2.89%
liver therapeutics international efruxifermin
Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis
Published: 2022-06-27 (Crawled : 11:00) - ir.akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.0%
H: 0.87%
C: -2.89%
fibrosis liver therapeutics international nash efruxifermin
Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment
Published: 2021-07-08 (Crawled : 15:15) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: -0.46%
H: 3.63%
C: 0.25%
treatment fibrosis drug nash liver
Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-
Published: 2021-06-25 (Crawled : 16:00) - ir.akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.11%
H: 0.35%
C: -2.92%
diabetes liver efruxifermin
Increased adiponectin following efruxifermin treatment is associatedwith improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NASH
Published: 2021-06-25 (Crawled : 16:00) - akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.11%
H: 0.35%
C: -2.92%
treatment nash liver efruxifermin trial
Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients
Published: 2021-06-25 (Crawled : 16:00) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.11%
H: 0.35%
C: -2.92%
diabetes nash liver efruxifermin
Akero Therapeutics Presents Analyses at the 2021 International Liver Congress
Published: 2021-06-21 (Crawled : 14:00) - biospace.com/
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.73%
H: 0.23%
C: -2.29%
liver presentation therapeutics
Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, and metabolism, and in histologic parameters following treatment with efruxifermin
Published: 2021-06-21 (Crawled : 13:00) - akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.73%
H: 0.23%
C: -2.29%
treatment fibrosis correlation liver efruxifermin
The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial
Published: 2021-06-21 (Crawled : 12:15) - akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.73%
H: 0.23%
C: -2.29%
treatment nash liver trial
Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH
Published: 2021-06-21 (Crawled : 12:00) - ir.akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.73%
H: 0.23%
C: -2.29%
fibrosis nash liver
Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress
Published: 2021-06-01 (Crawled : 12:00) - ir.akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: -1.72%
H: 3.93%
C: 2.29%
presentation results liver efruxifermin
Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk At The Liver Meeting® 2020
Published: 2020-10-02 (Crawled : 15:25) - ir.akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: -1.34%
H: 1.95%
C: 0.69%
phase 2 liver efruxifermin nash phase 2b
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.